Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
- PMID: 10888034
Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
Abstract
Angiogenesis, or the sprouting of new blood vessels, is a central process in the growth of solid tumors. For many cancers, the extent of vascularization of a tumor is a negative prognostic indicator signifying aggressive disease and increased potential for metastasis. Recent efforts to understand the molecular basis of tumor-associated angiogenesis have identified several potential therapeutic targets, including the receptor tyrosine kinases for the angiogenic factor vascular endothelial growth factor (VEGF). Here we review the approach taken at SUGEN, Inc. to discover and develop small molecule inhibitors of receptor tyrosine kinases as anti-angiogenic agents. We focus on SU5416, a selective inhibitor of VEGF receptors that is currently in clinical development for the treatment of advanced malignancies. Its biochemical, biological and pharmacological properties are reviewed and clinical implications discussed.
Similar articles
-
Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.Microvasc Res. 2002 May;63(3):304-15. doi: 10.1006/mvre.2001.2383. Microvasc Res. 2002. PMID: 11969307
-
The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.Clin Cancer Res. 2000 Dec;6(12):4848-58. Clin Cancer Res. 2000. PMID: 11156244
-
SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.Cancer Res. 1999 Jan 1;59(1):99-106. Cancer Res. 1999. PMID: 9892193
-
Angiogenesis inhibition in solid tumors.Cancer J. 2001 Nov-Dec;7 Suppl 3:S120-8. Cancer J. 2001. PMID: 11779082 Review.
-
Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases.Curr Opin Chem Biol. 2004 Aug;8(4):432-41. doi: 10.1016/j.cbpa.2004.06.009. Curr Opin Chem Biol. 2004. PMID: 15288254 Review.
Cited by
-
Endometriosis-Associated Angiogenesis and Anti-angiogenic Therapy for Endometriosis.Front Glob Womens Health. 2022 Apr 5;3:856316. doi: 10.3389/fgwh.2022.856316. eCollection 2022. Front Glob Womens Health. 2022. PMID: 35449709 Free PMC article. Review.
-
FLT3 inhibitors: a story of the old and the new.Curr Opin Hematol. 2011 Mar;18(2):71-6. doi: 10.1097/MOH.0b013e3283439a03. Curr Opin Hematol. 2011. PMID: 21245757 Free PMC article. Review.
-
Design, synthesis and biological evaluation of novel indolin-2-ones as potent anticancer compounds.Bioorg Med Chem Lett. 2017 Aug 1;27(15):3326-3331. doi: 10.1016/j.bmcl.2017.06.019. Epub 2017 Jun 7. Bioorg Med Chem Lett. 2017. PMID: 28625363 Free PMC article.
-
Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification.BMC Cancer. 2003 Feb 7;3:3. doi: 10.1186/1471-2407-3-3. Epub 2003 Feb 7. BMC Cancer. 2003. PMID: 12657164 Free PMC article.
-
RTK Inhibitors in Melanoma: From Bench to Bedside.Cancers (Basel). 2021 Apr 2;13(7):1685. doi: 10.3390/cancers13071685. Cancers (Basel). 2021. PMID: 33918490 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources